Encephalitis resident survival guide: Difference between revisions
No edit summary |
MoisesRomo (talk | contribs) No edit summary |
||
Line 17: | Line 17: | ||
****[[Treponema pallidum]] | ****[[Treponema pallidum]] | ||
****[[Mycoplasma]] | ****[[Mycoplasma]] | ||
****[[Listeria monocytogenes]] | |||
****[[Borrelia burgdorferi]] | |||
****[[Brucellosis]] | |||
***Viral | ***Viral | ||
****[[Herpes simplex]] | ****[[Herpes simplex]] | ||
****[[Mumps]] | |||
****[[Rubella]] | |||
****[[Epstein-Barr virus]] | ****[[Epstein-Barr virus]] | ||
****[[Zoster]] | ****[[Zoster|Varicella zoster]] | ||
****[[Rabies]] | ****[[Rabies]] | ||
****[[HIV]] | ****[[HIV]] | ||
Line 41: | Line 46: | ||
===Common Causes=== | ===Common Causes=== | ||
Infectious | |||
*[[Herpes simplex]] | |||
*[[Mumps]] | |||
*[[Rubella]] | |||
*[[Epstein-Barr virus]] | |||
*[[Zoster|Varicella zoster]] | |||
==Diagnosis== | ==Diagnosis== | ||
Line 84: | Line 96: | ||
| colspan="1" rowspan="1" |'''Minor Criteria (2 required for possible encephalitis; ≥3 required for probable or confirmeda encephalitis):''' | | colspan="1" rowspan="1" |'''Minor Criteria (2 required for possible encephalitis; ≥3 required for probable or confirmeda encephalitis):''' | ||
|- | |- | ||
| colspan="1" rowspan="1" |Documented fever ≥38° C (100.4°F) within the 72 h before or after | | colspan="1" rowspan="1" |Documented fever ≥38° C (100.4°F) within the 72 h before or after presentation. | ||
|- | |- | ||
| colspan="1" rowspan="1" |Generalized or partial seizures not fully attributable to a preexisting seizure | | colspan="1" rowspan="1" |Generalized or partial seizures not fully attributable to a preexisting seizure disorder. | ||
|- | |- | ||
| colspan="1" rowspan="1" |New onset of focal neurologic findings | | colspan="1" rowspan="1" |New onset of focal neurologic findings. | ||
|- | |- | ||
| colspan="1" rowspan="1" |CSF WBC count ≥5/cubic | | colspan="1" rowspan="1" |CSF WBC count ≥5/cubic mm. | ||
|- | |- | ||
| colspan="1" rowspan="1" |Abnormality of brain parenchyma on neuroimaging suggestive of encephalitis that is either new from prior studies or appears acute in onset | | colspan="1" rowspan="1" |Abnormality of brain parenchyma on neuroimaging suggestive of encephalitis that is either new from prior studies or appears acute in onset. | ||
|- | |- | ||
| colspan="1" rowspan="1" |Abnormality on electroencephalography that is consistent with encephalitis and not attributable to another cause. | | colspan="1" rowspan="1" |Abnormality on electroencephalography that is consistent with encephalitis and not attributable to another cause. | ||
|- | |- | ||
|Do not modify | |Do not modify | ||
Line 103: | Line 115: | ||
==Do's== | ==Do's== | ||
Rule-out other causes of decreased level of consciousness and personality change, such as drug abuse. | |||
Take a carefull history to relatives when managing a comatose patient. | |||
Perform routine full haematological and biochemical blood screen. | |||
When performing a CSF analysis, collect at least 20 ml, if possible; freeze at least 5-10 ml fluid; document opening pressure, WBC count with differential, RBC count, protein, and glucose; Gram stain and bacterial culture. | |||
Be aware that the abscense of lucocitosis, focal neurological signs, fever, headache, and pleocytosis, is more suggestive of encephalopathy rather than encephalitis. | |||
RPR is prefered over VDRL for treponemal detection. | |||
MRI is prefered over CT scan for neuroimaging. | |||
<br /> | |||
==Don'ts== | ==Don'ts== | ||
Do not delay antiviral treatment, since mortality may reach up to 70% when not given. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 14:21, 12 January 2021
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Moises Romo M.D.
Synonyms and Keywords: encephalitis management, encephalitis workup, encephalitis approach,encephalitis management, encephalitis treatment, encephalitis diagnosis
Overview
Encephalitis refers to the inflammation of the brain. The causes of encephalitis are mostly infectious, being viruses, bacteria, fungi, or parasites the possible agents. Presentation usually involves headache, fever, confusion, neck stiffness (Kernig and Brudzinski signs), and vomiting. Diagnosis is typically based on clinical presentation and supported by blood tests, medical imaging, and analysis of cerebrospinal fluid. Rapid identification of encephalitis is crucial to reduce sequelae. Management is directed against the affecting agent (antivirals, antibiotics), reducing swelling, and supportive measures.
Causes
Life Threatening Causes
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.
- All causes of encephalitis may be potentially fatal or disabiling if left untreated in 24 hours.; among them:
- Infectious
- Bacterial
- Viral
- Fungal
- Protozoan
- Autoimmune
- Encephalitis lethargica
- Limbic encephalitis
- Infectious
Common Causes
Infectious
Diagnosis
Shown below is an algorithm summarizing the diagnosis of encephalitis according to the International Encephalitis Consortium guidelines:
Patient suspicious for encephalitis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PERFORM: • CSF analysis (at least 20 ml): Opening pressure, WBC count with differential, RBC count, protein, glucose, Gram stain and bacterial culture • Routine blood testing • Blood cultures • HSV-1/2 PCR • VZV PCR • Enterovirus PCR • Cryptococcal antigen and/or India Ink staining • Oligoclonal bands and IgG index • VDRL • HIV serology • Hold acute serum and collect convalescent serum 10–14 d later for paired antibody testing • Neuroimaging (MRI preferred to CT, if available) • Chest imaging (Chest x-ray and/or CT) • EEG | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evaluate further testing if additional risk factors are present | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Host factors | Geographic factors | Season and exposure | Specific signs and symptoms | Laboratory features | Neuroimaging features | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immunocompromised: • CMV PCR • HHV6/7 PCR • HIV PCR (CSF) • Toxoplasma gondii serology and/or PCR • MTB testing • Fungal testing • WNV testing | Africa: • Malaria (blood smear) • Trypanosomiasias (blood/CSF smear • Serology from serum and CSF) • Dengue testing | Summer/Fall: • Arbovirusd and tick-borne disease testing | Psychotic features or movement disorder: • Anti-NMDAR antibody (serum, CSF) • Rabies testing • Screen for malignancy • Creutzfeld-Jakobs disease | Elevated transaminases: • Rickettsia serology • Tick borne diseases testing | Frontal lobe: • Naegleria fowleri testing (CSF wet mount and PCRg) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Asia: • Japanese encephalitis virus testing • Dengue testing • Malaria (blood smear) • Nipah virus testing | Cat exposure (particularly if with seizures, paucicellular CSF): • Bartonella antibody (serum), ophthalmologic evaluation | Prominent limbic symptoms: • Autoimmune limbic encephalitis testing • HHV6/7 PCR (CSF) • Screen for malignancy | CSF protein >100 mg/dL, or CSF glucose <2/3 peripheral glucose, or lymphocytic pleocytosis with subacute symptom onset: • MTBtestingb • Fungal testing | Temporal lobe: • VGKC antibodies (serum and CSF) • HHV 6/7 PCR (CSF) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Australia: • Murray Valley encephalitis virus testingd • Kunjin virus testingd • Australian Bat Lyssavirus (ABLV) testing | Tick exposure: • Tick borne disease testing | Rapid decompensation (particularly with animal bite history or prior travel to rabies-endemic areas): • Rabies testing | CSF protein >100 mg/dL or CSF glucose <2/3 peripheral glucose and neutrophilic predominance with acute symptom onset and recent antibiotic use: • CSF PCR for S. pneumoniae and N. meningiditis | Basal ganglia and/or thalamus: • Arbovirusd testing • MTB testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Europe: • Tick-borne encephalitis virus (serology) | Animal bite/bat exposure: • Rabies testing | Respiratory symptoms: • Mycoplasma pneumoniae serology and throat PCR (if either positive, then do CSF PCR) • Respiratory virus testing | CSF eosinophilia: • MTB testingb • Fungal testingc • Baylisascaris procyonis antibody (serum) • Angiostrongylus cantonensis and Gnathostomasp. testing | Brainstem: • Arbovirus testingd • Listeria PCR(if available) • Brucella antibody (serum) • MTB testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Southern Europe: • WNV testing • Toscana virus testing | Swimming or diving in warm freshwater or nasal/sinus irrigation: • Naegleria fowleri (CSF wet mount and PCR) | Acute flaccid paralysis: • Arbovirus testingd • Rabies testing | RBCs in CSF: • Naegleria fowleri testing | Cerebellum: • EBV PCR (CSF) and serology | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Central and South America: • Dengue testingd • Malaria (blood smear) • WNV • Venezuelan equine encephalitis testing | Parkinsonism: • Arbovirus testingd • Toxoplasma serology | Hyponatremia—anti: • VGKC antibody (serum) • MTB testing | Diffuse cerebral edema: • Respiratory virus testing | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
North America: • Geographically appropriate arboviral testing (eg, WNV, Powassan, LaCrosse, Eastern Equine Encephalitis virusesd, Lyme(serum ELISA and Western blot) | Nonhealing skin lesions: • Balamuthia mandrillaris • Acanthamoeba testing | Space occupying and/or ring-enhancing lesions: • MTB testingb • Fungal testingc • Balamuthia mandrillaris and Acanthamoeba testingg • Toxoplasma serology | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hydrocephalus and/or basilar meningeal enhancement: • MTB testingb • Fungal testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Infarction or hemorrhage: • MTB testing • Fungal testing • Respiratory virus testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diagnostic Criteria for Encephalitis and Encephalopathy of Presumed Infectious or Autoimmune Etiology according to the International Encephalitis Consortium |
Major Criterion (required): |
Patients presenting to medical attention with altered mental status (defined as decreased or altered level of consciousness, lethargy, or personality change) lasting ≥24 h with no alternative cause identified. |
Minor Criteria (2 required for possible encephalitis; ≥3 required for probable or confirmeda encephalitis): |
Documented fever ≥38° C (100.4°F) within the 72 h before or after presentation. |
Generalized or partial seizures not fully attributable to a preexisting seizure disorder. |
New onset of focal neurologic findings. |
CSF WBC count ≥5/cubic mm. |
Abnormality of brain parenchyma on neuroimaging suggestive of encephalitis that is either new from prior studies or appears acute in onset. |
Abnormality on electroencephalography that is consistent with encephalitis and not attributable to another cause. |
Do not modify |
Treatment
Shown below is an algorithm summarizing treatment of encephalitis according to the American Academy of Neurology guidelines:
Do's
Rule-out other causes of decreased level of consciousness and personality change, such as drug abuse.
Take a carefull history to relatives when managing a comatose patient.
Perform routine full haematological and biochemical blood screen.
When performing a CSF analysis, collect at least 20 ml, if possible; freeze at least 5-10 ml fluid; document opening pressure, WBC count with differential, RBC count, protein, and glucose; Gram stain and bacterial culture.
Be aware that the abscense of lucocitosis, focal neurological signs, fever, headache, and pleocytosis, is more suggestive of encephalopathy rather than encephalitis.
RPR is prefered over VDRL for treponemal detection.
MRI is prefered over CT scan for neuroimaging.
Don'ts
Do not delay antiviral treatment, since mortality may reach up to 70% when not given.